Skip to main content
    T

    Terns Pharmaceuticals Inc (TERN)

    Official site

    BIOTECHNOLOGY

    $52.95
    +0.00 (+0.00%)

    Last updated: May 05, 2026 at 5:00 PM ET

    Terns Pharmaceuticals Inc (TERN) Financials: Revenue, Profit and Cash Flow

    Updated Mar 31, 2026. Financial statements from company filings, amounts in US dollars.

    Terns Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$96.21M, operating cash flow was -$82.18M and free cash flow was -$82.18M. The quarter ended Dec 31, 2025 had revenue of $0 and net income of -$23.57M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $110.12M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0-100.0%N/AN/AN/A
    Dec 2021$1.00MN/A100.0%-4986.0%-5015.8%
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Dec 2025, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Revenue$0$0$0$0$1.00M$0$0$0
    Cost of revenue$0$0$0$0$0$0$195.00K$65.00K
    Gross profit$0$0$0$0$1.00M$0-$195.00K-$65.00K
    Research and development$77.89M$70.11M$63.50M$39.62M$31.31M$28.03M$61.53M$14.55M
    Operating income-$110.12M-$101.87M-$102.56M-$62.03M-$49.86M-$37.02M-$70.20M-$18.45M
    Net income-$96.21M-$88.85M-$90.21M-$60.34M-$50.16M-$40.57M-$68.82M-$17.71M
    EBITDA-$109.72M-$100.99M-$101.99M-$60.98M-$48.43MN/A-$68.64M-$18.39M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Revenue$0$0$0$0$0$0$0$0$1.32M$0$0$0
    Gross profit$108.00K$0$0$0N/A$0$0$0$1.10M$0$0$0
    Operating income-$27.60M-$27.72M-$27.38M-$27.43M-$25.95M-$24.94M-$25.54M-$25.45M-$24.06M-$33.18M-$21.16M-$24.16M
    Net income-$23.57M-$24.64M-$24.09M-$23.91M-$21.80M-$21.95M-$22.74M-$22.37M-$21.02M-$29.77M-$17.90M-$21.53M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $474.00K by $524.27M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$1.03B$363.93M$268.52M$287.03M$168.07M$92.29M$23.90M$89.07M
    Current assets$1.02B$362.11M$267.43M$285.19M$166.93M$90.87M$22.22M$88.48M
    Cash and equivalents$524.75M$161.44M$79.93M$143.24M$47.70M$74.85M$12.33M$82.52M
    Total liabilities$18.55M$18.06M$13.15M$10.08M$7.77M$23.70M$5.58M$16.84M
    Short-term debt$474.00K$428.00K$603.00K$661.00K$0$12.88MN/AN/A
    Shareholder equity$1.01B$345.87M$255.37M$276.94M$160.30M-$117.44M$4.21M$72.23M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Total assets$1.03B$301.65M$320.42M$339.31M$363.93M$378.23M$230.88M$246.77M$268.52M$271.69M$289.70M$301.29M
    Total liabilities$18.55M$17.59M$15.19M$13.27M$18.06M$13.76M$12.20M$10.05M$13.15M$13.26M$15.55M$13.60M
    Cash and equivalents$524.75M$150.70M$145.97M$139.02M$161.44M$270.14M$91.50M$65.10M$79.93M$37.89M$80.92M$184.35M
    Shareholder equity$1.01B$284.07M$305.23M$326.04M$345.87M$364.47M$218.68M$236.72M$255.37M$258.43M$274.15M$287.68M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$82.18M-$70.02M-$67.39M-$49.11M-$41.83M-$29.81M-$66.22M-$18.07M
    Capital expenditures$0$42.00K$52.00K$275.00K$340.00K$584.00K$900.00K$244.00K
    Free cash flow-$82.18M-$70.06M-$67.44M-$49.38M-$42.17M-$30.39M-$67.12M-$18.32M
    Investing cash flow-$298.04M-$12.41M-$37.99M-$22.27M-$119.70M$6.69M-$3.86M-$4.78M
    Financing cash flow$743.51M$164.00M$41.95M$167.09M$134.39M$85.52M$62.00K$99.76M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemDec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
    Operating cash flow-$19.08M-$19.77M-$18.88M-$24.44M-$14.58M-$16.45M-$16.18M-$22.80M-$19.32M-$20.70M-$12.99M-$14.38M
    Capital expenditures$0$0$0$0$0$0$13.00K$29.00K$44.00K$8.00K$0$0
    Free cash flow-$19.08M-$19.77M-$18.88M-$24.44M-$14.58M-$16.45M-$16.19M-$22.83M-$19.36M-$20.71M-$12.99M-$14.38M
    Last 12 quarters

    Frequently Asked Questions About TERN

    What is Terns Pharmaceuticals' annual revenue?

    Terns Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Terns Pharmaceuticals profitable?

    No. Terns Pharmaceuticals reported net income of -$96.21M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does TERN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$82.18M minus capital expenditures of $0 produced free cash flow of -$82.18M.

    How much debt does Terns Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $474.00K and cash and equivalents of $524.75M.